The therapy cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
Some of the cutaneous adverse events to amivantamab, which targets both EGFR and MET, can be severe and have atypical presentations, which led to dose reductions in five of six cases.
Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.
Standard of care for patients with EGRF+ lung cancer is treatment with an EGRF targeted drug, but should this be monotherapy, or should it be combined with chemotherapy and/or other drugs?